Adial Pharmaceuticals Inc. | Press Release

archive,category,category-press-release,category-96,ajax_fade,page_not_loaded,,qode-theme-ver-16.2.1,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive

Press Release

Posted at 12 Feb, 14:39h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

Posted at 07 Feb, 14:31h in Press Release by adialpharma 0 Comments

0 Likes

DR. BANKOLE A. JOHNSON, CHAIRMAN OF ADIAL PHARMACEUTICALS, RECEIVES PRESTIGIOUS AMERICAN SOCIETY OF ADDICTION MEDICINE AWARD

Posted at 01 Feb, 14:25h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder

Posted at 30 Jan, 14:25h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants

Posted at 18 Jan, 15:09h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

Posted at 15 Jan, 15:35h in Press Release by adialpharma 0 Comments

0 Likes

Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series

Posted at 10 Jan, 15:27h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals to Present at The 2019 Wall Street Conference

Posted at 24 Dec, 14:58h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Retires All Outstanding Debt

Posted at 19 Dec, 15:03h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group

Posted at 13 Dec, 15:29h in Press Release by adialpharma 0 Comments

0 Likes

Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl